Coherus Oncology (CHRS) Retained Earnings (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Retained Earnings data on file, last reported at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 5.32% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 5.32% YoY), and the FY2025 full-year result was $1.4 billion, up 525251.27% from the prior year.
• Retained Earnings advanced to $1.5 billion in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.5 billion in Q1 2026 to a low of -$1.5 billion in Q2 2023.
• A 5-year average of $93.8 million and a median of -$272000.0 in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings sank 540717.04% in 2023 and surged 525251.27% in 2025, its largest moves.
• Tracing CHRS's Retained Earnings over 5 years: stood at -$1.3 billion in 2022, then soared by 203.33% to $1.4 billion in 2023, then sank by 100.02% to -$275000.0 in 2024, then surged by 525251.27% to $1.4 billion in 2025, then gained by 3.88% to $1.5 billion in 2026.
• Business Quant data shows CHRS's Retained Earnings at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and -$1.3 billion in Q3 2025.